•
MN
MNPR
Monopar Therapeutics Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
470.39M
Volume
379.22K
52W High
$105.00
52W Low
$26.06
Open
$0.00
Prev Close
$70.32
Day Range
0.00 - 0.00
About Monopar Therapeutics Inc. Common Stock
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Latest News
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
GlobeNewswire Inc.•Nov 9
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.•Sep 24
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
GlobeNewswire Inc.•Sep 24
Monopar Therapeutics Reports Third Quarter 2024Â Financial Results and Recent Developments
GlobeNewswire Inc.•Nov 8
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
GlobeNewswire Inc.•Oct 29
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
GlobeNewswire Inc.•Jun 25
Monopar and NorthStar Amend & Extend Collaboration
GlobeNewswire Inc.•Jun 11
Monopar Announces CFO Succession
GlobeNewswire Inc.•May 24